Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
General Hospital of Athens "Gennimatas", Athens, Greece
Semmelweis University Faculty of Medicine, Budapest, Hungary
University of Pécs Medical School, Pécs, Hungary
UCLA Gonda Diabetes Center, Los Angeles, California, United States
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Nucleus Network, Melbourne, Victoria, Australia